Patient and public involvement in health research: A Nordic perspective

ANNE-SOFIE SAND1,2*, SAMELINE GRIMSGAARD1,2 & INGVILD PETTERSEN1

1Clinical Research Department, University Hospital of North Norway, Norway, and 2UiT The Arctic University of Norway, Norway

Abstract
Patient and public involvement (PPI) in health research is of increasing interest internationally, as well as being a means to enhance the quality and relevance of research. PPI was one of the main themes and parallel sessions at The Nordic Health Research and Innovation Networks in Oslo in 2017. In this short comment/debate article, we outline some of the experiences from the event. Importantly, there are many common challenges. More collaboration across the borders could ensure a broader range of experience in the field and provide better ways of developing and evaluating PPI in health research.

Keywords: patient and public involvement, health research quality and relevance, Nordic collaboration

Introduction
Patient and public involvement (PPI) is a topic of increasing interest and relevance internationally, as well as in health research [1–3]. PPI is quite a new concept and is often used interchangeably with terms such as patient engagement or empowerment, participatory health care, co-researching, co-production and many more [4,5]. However, in the context of clinical research, ‘patient and public involvement’ seems to be the preferred term. There are two main reasons for involving patients and members of the public in research. One is as means of enhancing quality and relevance in research; the other is as part of democratic principles. In the case of the latter, PPI is also regarded as a way of empowering people who use health and social care services [6]. When aiming at reduced waste and increased value in research, the needs of the potential users of the research should be of particular interest for the research communities [7]. Major funding bodies, such as the European Research Council, encourage or require PPI in health research in their calls, depending on the topic [8].

Based on existing literature and the experiences from The Nordic Health Research and Innovation Networks (NRI) conference in Oslo in 2017, we briefly report some of the main features of PPI. Furthermore, we describe how the Nordic countries are approaching the field and propose possible benefits of more Nordic collaboration.

Internationally, the UK has been a leading nation in developing good systems for PPI. One important initiative is the James Lind Alliance (JLA) [9]. The JLA is a non-profit-making initiative where patients, carers and clinicians meet to discuss key uncertainties in health research in the UK. In this way, all these groups can influence research priorities. The government-funded organisation INVOLVE [6] was established back in 1996, aiming to support public involvement in health and social care research. The INVOLVE website updates information on areas such as practical guidelines for researchers and inspiring examples of collaborations in the field. PPI is defined by INVOLVE as ‘research being carried out “with” or “by” members of the public instead of “to”, “about”
or “for” them [6]. Patients or members of the public are present as important stakeholders when research funding and prioritising are discussed. On a more practical level, patients give their advice when researchers discuss and plan methodology and study design. The users of research are commonly defined as patients or next of kin, but on some occasions they are simply members of the public. The nature of the research and the research question will decide which kind of involvement is relevant. How to recruit the right patients is a matter of continuous discussion. Most commonly, patient and user organisations form the basis for recruitment. Frequently mentioned challenges are questions of capacity, payment, training and a non-desirable development of ‘professionalism’ of patients involved in PPI. Hence, it is of crucial importance that PPI is well organised in order actually to support involvement and remove possible barriers. However, a major issue is also that so far the evidence for added value from PPI in research is limited, and it should therefore be investigated further [2].

**Nordic countries: status**

Among the Nordic countries, only Norway has introduced considerations for PPI as mandatory for research funding by the Regional Health Authorities [10]. The Research Council of Norway and the Norwegian Cancer Society also emphasise the value of PPI and follow the same practice. Denmark and Sweden have so far not institutionalised general guidelines, but PPI is on the agenda, especially as a prerequisite for research funding. According to information from the Academy of Finland, PPI is not a prerequisite for research funding in Finland [11].

In Denmark, a report published back in 2011 gave recommendations about how PPI can be an important part of research [12]. However, according to reports from a national conference in 2017, there is a concern that the pharmaceutical industry is now partly dominating the field. As such, traditional roles in the research field are challenged as a result of PPI, thereby creating a need for new competence for both professionals and patients [13].

In Sweden, collaborators at The Centre for Ageing and Supportive Environments (CASE) at Lund University have written a report on PPI and patient involvement, published by the Swedish Research Council for Health, Work and Welfare [14]. The report confirms that PPI is increasingly acknowledged as an important part of health research. However, it is questioned whether the researchers really value the effort and contribution from participants. According to the authors of the report, PPI must be scientifically grounded.

**Patient initiatives**

In order to succeed in involving patients in research, it is necessary to build patient-led organisations. In Finland, Siskot (sisters) is an independent organisation founded and run by women living with cancer. Siskot focuses on the need for information when participating in clinical trials. In order to receive better treatment, patients need to be able to contribute and not be over-protected in health research [15].

In Norway, research networks in mental health offer training and have involved service users or patients as co-researchers. This initiative has resulted in hypotheses on how participatory research can be fruitfully organised [16]. The European Patients’ Academy on Therapeutic Innovation (EUPATI) is another patient-led initiative, coordinated by The European Patients’ Forum [17]. The main goal is to develop and disseminate objective, credible, user-friendly and up-to-date information regarding the development of new treatments. Offering training and education for patients involved in PPI is important for the initiative. Several nations in Europe have established national platforms of EUPATI. Denmark, Norway and Finland have now established their arms of the network.

**The way ahead: Nordic collaboration**

In order to increase and enhance PPI, it is important that initiatives come from patient organisations as well as the researcher communities and health authorities. According to the presentations and the debate at the NRI conference, PPI activities in the Nordic countries have so far been largely dominated by top-down initiatives, such as reports and guidelines initiated by the government. Several participants at the conference highlighted the importance of more bottom-up initiatives. In this regard, national initiatives such as Siskot in Finland and the internationally oriented EUPATI hold promising potential.

Furthermore, Nordic collaboration could ensure a broader range of experiences for developing and evaluating PPI. One possible area for collaboration is by arranging courses and training for researchers with participants from all the Nordic countries, for example as part of PhD education.

When aiming at better use of PPI and thereby enhancing relevance and quality in health research, it is crucial to build a culture of mutual trust and a better understanding of the concept. Exchanging views and experiences in the field at the NRI conference convinced us that more initiatives are needed to bring the stakeholders closer together. It is our hope that the Nordic health research community recognises this need and integrates the matter of PPI in all
aspects when planning and facilitating of research are on the agenda.

Acknowledgements
We would like to thank the main presenter at the NRI Conference, Professor Louise Locock, University of Oxford and University of Aberdeen. Furthermore, we highly appreciated the contributions from the following: Prof. Mogens Hörder, University of Southern Denmark; researcher Oskar Jonsson, Lund University, Sweden; Tiina Aaltonen, Siskot, Finland; Ole Alexander Opdalshei, the Norwegian Cancer Society; and Lilly Ann Elvestad, the Norwegian Federation of Organizations of Disabled People/Health&Care21.

Declaration of conflicting interests
The authors declare that there is no conflict of interest.

Funding
The Nordic Trial Alliance provided financial support for the NRI conference and the following work with this paper.

ORCID iD
Anne-Sofie Sand https://orcid.org/0000-0002-4425-2029

References
[1] Brett J, Staniszewska S, Simera I, et al. Reaching consensus on reporting patient and public involvement (PPI) in research: methods and lessons learned from the development of reporting guidelines. BMJ Open 2017;7:e016948.
[2] Petit-Zeman S and Locock L. Health care: bring on the evidence. Nature 2013;501:160–161.
[3] Locock L, Boylan AM and Snow R. The power of symbolic capital in patient and public involvement in health research. Health Expect 2017;20:836–844.
[4] Manafio E, Petermann L, Mason-Lai P, et al. Patient engagement in Canada: a scoping review of the ‘how’ and ‘what’ of patient engagement in health research. Health Res Policy Syst 2018;16:5.
[5] Castro EM, Van Regenmortel T, Vanhaeckt K, et al. Patient empowerment, patient participation and patient-centeredness in hospital care: a concept analysis based on a literature review. Patient Educ Coun 2016;99:1923–1939.
[6] National Institute for Health Research. INVOLVE, www.invo.org.uk (accessed 10 April 2019).
[7] Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when research priorities are set. Lancet 2014;383:156–164.
[8] The Research Council of Norway, https://www.forskning-sradet.no/en/about-the-research-council/programmes/bedre-helse-og-livskvalitet/ (accessed 5 April 2019).
[9] James Lind Alliance, www.jla.nihr.ac.uk/about-the-james-lind-alliance/ (accessed 10 April 2019).
[10] Vedtatte retningslinjer – brukermedvirkning i helseforskning i Norge, https://helse-nord.no/Documents/Forskning/Forskningsmidler/2020%20Forskningsmidler/Veileder%20brukermedvirkning%20mai%202018.pdf#-2015%29.pdf (accessed 10 April 2019).
[11] Academy of Finland, www.aka.fi (accessed 5 April 2018).
[12] Sundhedsforsknning – et samarbejde mellem forskere og brugere, Danmark 2011. http://pure.au.dk/portal/files/48483162/NSS_2012_Sundhedsforsknning_et_samarbejde_mellem_forskere_og_brugere.pdf (accessed 10 April 2019).
[13] VIVE – Det Nationale Forsknings- og Analysecenter for velferd, https://www.kora.dk/udgivelser/udgivelse/i14608/Debat-Patienter-skal-inddrages-i-medicinsk-forskning/ (accessed 10 July 2019).
[14] Forte. Research brief: user participation, http://forte.se/en/publication/user-participation/ (accessed 10 April 2019).
[15] Aaltonen T. Patient’s perspectives on the ethical evaluation of clinical trials. Presentation at the NRI Conference, https://anta.nordforsk.org/files/AaltonenTiinaPatientsPerspectivesontheEthicalEvaluation.pdf (accessed 10 April 2019).
[16] Moltu C, Stefansen J, Svisdahl M, et al. Negotiating the coresearcher mandate – service users’ experiences of doing collaborative research on mental health. Disabil Rehabil 2012;34:1608–1616.
[17] EUPATI, https://www.eupati.eu/eupati-network/ (accessed 8 April 2019).